{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:08:34Z","timestamp":1792807714693,"version":"4.5.0"},"reference-count":14,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2006,3,30]],"date-time":"2006-03-30T00:00:00Z","timestamp":1143676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2006,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Rapid fistula healing may predispose Crohn's disease patients to abscess development.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> Data from ACCENT II were analysed to determine whether fistula\u2010related abscess development is affected by infliximab exposure.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Following infliximab 5\u2003mg\/kg infusions at weeks 0, 2 and 6, patients were evaluated for fistula response for two consecutive visits at least 4\u2003weeks apart. Patients (<jats:italic>N<\/jats:italic>\u2003=\u2003282) were randomized at week 14 to either placebo or infliximab 5\u2003mg\/kg every 8\u2003weeks through week 46. If response was lost at or after week 22, patients could crossover to a 5\u2003mg\/kg higher infliximab dose. Fistula\u2010related abscesses were diagnosed by physical examination or by imaging procedures according to usual practice.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Infliximab exposure was approximately twofold higher for the infliximab maintenance group. Twenty\u2010one (15%) patients in the infliximab maintenance group had at least one newly developed fistula\u2010related abscess compared with 27 (19%) in the placebo maintenance group (<jats:italic>P<\/jats:italic>\u2003=\u20030.526). The proportion of patients with a new fistula\u2010related abscess was similar regardless of whether or not patients crossed over to a 5\u2003mg\/kg higher infliximab dose. The number of fistula\u2010related abscesses diagnosed over time did not differ between groups.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Abscess development in patients with fistulizing Crohn's disease is not dependent on cumulative infliximab exposure.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2006.02878.x","type":"journal-article","created":{"date-parts":[[2006,3,30]],"date-time":"2006-03-30T09:49:25Z","timestamp":1143712165000},"page":"1127-1136","source":"Crossref","is-referenced-by-count":94,"title":["Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study"],"prefix":"10.1111","volume":"23","author":[{"given":"B. E.","family":"SANDS","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"BLANK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. H.","family":"DIAMOND","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"BARRETT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. J.","family":"VAN DEVENTER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,3,30]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.18165"},{"key":"e_1_2_6_3_2","first-page":"589","volume-title":"Inflammatory Bowel Diseases","author":"West R","year":"2003"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200203000-00007"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00392-5"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905063401804"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200303000-00003"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01427.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-004-6111-6"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(02)05909-9"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00414-8"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(05)00759-7"},{"key":"e_1_2_6_14_2","first-page":"A\u2010580","article-title":"Safety of infliximab and other Crohn's disease therapies \u2013 updated TREAT Registry data with over 10,000 patient\u2010years of follow\u2010up","volume":"128","author":"Lichtenstein GR","year":"2005","journal-title":"Gastroenterology"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.01.048"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2006.02878.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2006.02878.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T09:48:05Z","timestamp":1697190485000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2006.02878.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,30]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["10.1111\/j.1365-2036.2006.02878.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2006.02878.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,30]]}}}